Antibody-drug conjugates in solid tumors: Efficacy, challenges, and opportunities
{{output}}
Antibody-drug conjugates (ADCs) have become an increasingly important component of the therapeutic landscape of many solid tumors. Currently, there are eight ADCs approved for solid tumors, with hundreds being developed and in clinical trials. Initially being ... ...
